Brief: Aileron Therapeutics Announces Enrollment Expansion For Upcoming Phase 1B Clinical Trial Of ALRN-6924 In Patients With Advanced Non-Small Cell Lung Cancer
02/03/2021 12:21
March 2 (Reuters) - Aileron Therapeutics Inc ALRN.O :
* AILERON THERAPEUTICS ANNOUNCES ENROLLMENT EXPANSION FOR
UPCOMING
PHASE 1B CLINICAL TRIAL OF ALRN-6924 IN PATIENTS WITH ADVANCED
NON-SMALL CELL LUNG CANCER (NSCLC)
* AILERON THERAPEUTICS - TRIAL ANTICIPATED TO BEGIN IN Q2
2021
WITH INITIAL DATA ANTICIPATED AT END OF 2021 AND FINAL RESULTS
MID-2022
Source text for Eikon: ID:nGNX9Sz9NG
Further company coverage: ALRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rein Therapeutics
See all newsBrief: Rein Therapeutics Receives U.S. FDA Fast Track Designation For Lti-03 In Idiopathic Pulmonary Fibrosis
Rein Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Rein Therapeutics Q2 net loss narrows on lower R&D spending
Rein Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering